Patents by Inventor Xiaowu Pang

Xiaowu Pang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mammal-specific Growth-defective Arbovirus
    Publication number: 20210222132
    Abstract: Arbovirus carries an altered furin cleavage site that results in enhanced cleavage of a precursor polyprotein, such as, prE2 or prM. Dengue virus particles can have an amino acid alteration within amino acids 80-130 of prM. Zika virus particles can have alterations at amino residues at and/or about the furin cleavage site. The virus can be produced in insect cells. The virus does not form progeny virus in mammal cells.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 22, 2021
    Inventors: Xiaowu Pang, Xinbin Gu
  • Flavivirus Vaccine
    Publication number: 20180340011
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Application
    Filed: August 6, 2018
    Publication date: November 29, 2018
    Inventors: Xiaowu Pang, Xinbin Gu
  • Flavivirus vaccine
    Patent number: 10040824
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 7, 2018
    Assignee: Tengen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu
  • SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
    Publication number: 20160243214
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Application
    Filed: October 26, 2015
    Publication date: August 25, 2016
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • Subgenomic replicons of the flavivirus dengue
    Patent number: 9169297
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: October 27, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
    Publication number: 20120107358
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Application
    Filed: September 23, 2011
    Publication date: May 3, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • Subgenomic replicons of the flavivirus dengue
    Patent number: 8048427
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: November 1, 2011
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
    Publication number: 20100233210
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 16, 2010
    Applicants: Department of Health and Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • Virus-Like Particle Containing A Dengue Recombinant Replicon
    Publication number: 20090197319
    Abstract: A diagnostic assay for detecting antibody, in part, to human papilloma virus includes a virus-like particle that expresses human papilloma virus antigen.
    Type: Application
    Filed: January 9, 2008
    Publication date: August 6, 2009
    Applicant: TenGen Biomedical Company
    Inventor: Xiaowu Pang
  • Virus-like particle containing a Dengue virus recombinant replicon
    Publication number: 20090149405
    Abstract: The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has immunity effects. Further, different dengue virus types can be used to repeatedly produce efficient immune response, which strengthen body's immune response against the pathogen containing such antigen. Such vaccine can prevent and cure cancer and viral diseases.
    Type: Application
    Filed: May 30, 2008
    Publication date: June 11, 2009
    Applicant: TENGEN BIOMEDICAL CO.
    Inventor: Xiaowu Pang
  • Subgenomic replicons of the flavivirus dengue
    Patent number: 7524508
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: April 28, 2009
    Assignee: The United states of America as represented by the Department of Health and Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • FLAVIVIRUS VACCINE
    Publication number: 20070249032
    Abstract: Replicon virus-like particles can be used as flavivirus vaccines.
    Type: Application
    Filed: January 11, 2007
    Publication date: October 25, 2007
    Applicant: TenGen Biomedical Company
    Inventors: Xiaowu Pang, Xinbin Gu
  • Virus-like particle containing a dengue virus recombinant replicon
    Publication number: 20060018928
    Abstract: The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has immunity effects. Further, different dengue virus types can be used to repeatedly produce efficient immune response, which strengthen body's immune response against the pathogen containing such antigen. Such vaccine can prevent and cure cancer and viral diseases.
    Type: Application
    Filed: July 29, 2005
    Publication date: January 26, 2006
    Inventor: Xiaowu Pang
  • Subgenomic replicons of the flavivirus dengue
    Publication number: 20040265338
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Application
    Filed: September 5, 2003
    Publication date: December 30, 2004
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang